Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

ConV2X Releases Final Agenda Focused on AI, Clinical Development, FDA Regulation and ...

8 September 2026 · By · Wire by Fusion42

Published

8 September 2026

Topic

opportunities

◆ Sectors

Health

◆ Geography

United States

◆ Source

Read at biospace.com →

◆ Verified

Fusion42 · 8 September 2026 · Fusion42 review

ConV2X will host a multidisciplinary executive summit on Sept 24-25 in Cambridge, MA, focusing on AI, clinical development, FDA regulation, pharmaceutical data integrity, and decentralized technologies impacting life sciences.

This Wire brief sits within Fusion42's coverage of Health.

◆ ◆ The Wire takeaway

You must prepare for tighter regulatory demands on AI validation and clinical data integrity as FDA and global agencies clarify standards. This opens an opportunity for platforms that help pharma firms ensure compliant, auditable AI adoption.

◆ Coverage

1 source · 8 Sep 2026

◆ Related on Wire

◆ Topics

Healthaiclinical-developmentfda-regulationpharma-data-integritydecentralized-tech